Hyderabad, Jun 16 : Suven Life Sciences Limited (Suven) today announced that the Japanese Patent Office (JPO) has issued two product Patents to their New Chemical Entities (NCE's) for treating disorders associated with Neurodegenerative diseases.The patents -- 4455992 and 4473120 -- were valid till 2022. With this, a total of three Japanese product patents were granted to Suven, a company release said.The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven and were being developed as therapeutic agents. According to the invention 4460446 patent disclosure, the compounds were useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimers, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.Suven had secured intellectual property protection for several of its NCEs in major markets like US, Canada, Europe, China, Russia, India, Japan, Australia, New Zealand, Brazil and Mexico. These patents were exclusive intellectual property of Suven and achieved through the internal drug discovery research efforts. Products from these inventions would be outlicensed at the stage of clinical Phase-I or Phase-II.''We are very pleased by the grant of these patents to Suven by Japanese Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated market potential of 20 billion US Dollars globally,'' Suven CEO Venkat Jasti said.
==============================================
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment